BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN7945 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN7945\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06669247-3407@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20331111
DTEND;VALUE=DATE:20331112
SUMMARY:REGN7945: Phase 1/2 readout est. (NCT06669247)
DESCRIPTION:REGN7945\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to Ass
 ess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Lin
 voseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
 \nEstimated primary completion: 11 November 2033. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/regn7945#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06669247
URL:https://assetmemo.bio/drug/regn7945#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
